Consortium PSYCHIATRICUMConsortium PSYCHIATRICUMConsortium PSYCHIATRICUM2712-76722713-2919Eco-Vector11010.17816/CP110RESEARCHИССЛЕДОВАНИЕResearch ArticlePlasma levels of neurotrophic factors are not associated with the severity of depressionСодержание нейроторофических факторов в плазме крови не ассоциировано с тяжестью проявления депрессииhttps://orcid.org/0000-0003-0247-2717ZorkinaYana A.ЗоркинаЯна А.
Russian Federation

Senior researcher, Department of Basic and Applied Neurobiology

zorkina.ya@serbsky.ruhttps://orcid.org/0000-0002-4334-160157200207189SyunyakovTimur S.СюняковТимур С.
Russian Federation

PhD, Senior researcher

sjunja@bk.ruhttps://orcid.org/0000-0001-8793-1833AbramovaOlga V.АбрамоваОльга В.
Russian Federation

junior researcher, Department Basic and Applied Neurobiology

abramova1128@gmail.comhttps://orcid.org/0000-0001-6283-6258YunesRoman A.ЮнесРоман А.
Russian Federation

PhD, Vavilov Institute of General Genetics

editor@consortium-psy.comhttps://orcid.org/0000-0003-2742-552X55350951600PavlichenkoAleksey V.ПавличенкоАлексей В.
Russian Federation

PhD, Senior lecturer, Education Center

apavlichenko76@gmail.comPavlovKonstantin A.ПавловКонстантин А.
Russian Federation

PhD, Department Basic and Applied Neurobiology

editor@consortium-psy.comhttps://orcid.org/0000-0002-4501-8576KhobtaElena B.ХобтаЕлена Б.
Russian Federation

Attending physician, Researcher

dr.khobta@gmail.comhttps://orcid.org/0000-0002-8505-8310SusloparovaDaria A.СуслопароваДарья А.
Russian Federation

Psychiatrist

editor@consortium-psy.comTsarapkinGrigory Y.ЦарапкинГригорий Ю.
Russian Federation

Doctor of Medicine

editor@consortium-psy.comhttps://orcid.org/0000-0002-3349-5391AndreyukDenis S.АндреюкДенис С.
Russian Federation

PhD (biological sciences), senior fellow at the Education Center

denis.s.andreyuk@yandex.ruhttps://orcid.org/0000-0001-5780-0621DanilenkoValery N.ДаниленкоВалерий Н.
Russian Federation

Doctor of biology, professor

editor@consortium-psy.comhttps://orcid.org/0000-0001-6942-5531GurinaOlga I.ГуринаОльга И.
Russian Federation

Department Basic and Applied Neurobiology

editor@consortium-psy.comhttps://orcid.org/0000-0002-8681-5299MorozovaAnna Y.МорозоваАнна Юрьевна
Russian Federation

PhD, Senior researcher

hakurate77@gmail.comV. Serbsky National Medical Research Centre of Psychiatry and NarcologyФГБУ «Национальный медицинский исследовательский центр психиатрии и наркологии имени В.П. Сербского» Минздрава РоссииMental Health Clinic No.1 named after N.A. AlexeevГБУЗ «Психиатрическая клиническая больница № 1 им. Н.А. Алексеева»Vavilov Institute of General Genetics, Russian Academy of SciencesФГБУН «Институт общей генетики им. Н.И. Вавилова» Российской академии наукResearch Clinical Institute of Otorhinolaryngology of L.I. Svelzhevsky Department of Health of MoscowГБУЗ « Научно-исследовательский клинический институт оториноларингологии им. Л.И. Свержевского» Департамента здравоохранения города Москвы21122021311220212413222610202115112021Copyright ©; 2021, Zorkina Y.A., Syunyakov T.S., Abramova O.V., Yunes R.A., Pavlichenko A.V., Pavlov K.A., Khobta E.B., Susloparova D.A., Tsarapkin G.Y., Andreyuk D.S., Danilenko V.N., Gurina O.I., Morozova A.Y.Copyright ©; 2021, Зоркина Я.А., Сюняков Т.С., Абрамова О.В., Юнес Р.А., Павличенко А.В., Павлов К.А., Хобта Е.Б., Суслопарова Д.А., Царапкин Г.Ю., Андреюк Д.С., Даниленко В.Н., Гурина О.И., Морозова А.Ю.2021Zorkina Y.A., Syunyakov T.S., Abramova O.V., Yunes R.A., Pavlichenko A.V., Pavlov K.A., Khobta E.B., Susloparova D.A., Tsarapkin G.Y., Andreyuk D.S., Danilenko V.N., Gurina O.I., Morozova A.Y.Зоркина Я.А., Сюняков Т.С., Абрамова О.В., Юнес Р.А., Павличенко А.В., Павлов К.А., Хобта Е.Б., Суслопарова Д.А., Царапкин Г.Ю., Андреюк Д.С., Даниленко В.Н., Гурина О.И., Морозова А.Ю.https://creativecommons.org/licenses/by/4.0https://consortium-psy.com/jour/article/view/110

Depression is one of the most common mental illnesses. Impaired neurogenesis is observed in depression. Studying the concentration of biochemical indicators in the blood that may be involved in the pathogenesis of depression, looking for associations with the severity of depressive symptoms can be useful as an objective diagnosis of the disease and predicting the severity of the pathology. We determined plasma concentrations of the monoamine neurotransmitters serotonin and dopamine, and neurotrophic factors involved in neurogenesis (BDNF, CDNF and neuropeptide Y) in depressed patients and healthy volunteers with the same socio-demographic parameters using enzyme immunoassay and mass spectrometry. All study participants were administered the Hamilton Depression Scale (HAMD), the Generalized Anxiety Disorder Questionnaire (GAD-7), and the Center for Epidemiological Studies (CES-D). The cumulative scores on the three scales examined were significantly higher in depressed patients than in controls. The concentration of serotonin, dopamine, BDNF, CDNF, and neuropeptide Y in plasma did not differ between the subject groups and was not associated with the scores on the scales. Positive correlations were found between the content of neuropeptide Y and serotonin, BDNF and CDNF in blood plasma. Thus, although these markers are related to the pathophysiology of depression, they do not correlate with the severity of symptomatology and possibly in plasma cannot reflect processes occurring in the brain.

Депрессия - одно из самых распространенных психических заболеваний. Недостаток или снижение нейрогенеза у взрослых вызывает депрессию. Изучение концентрации биохимических показателей в крови, принимающих возможное участие в патогенезе депрессии, поиск ассоциаций с тяжестью депрессивной симптоматики может быть полезным в качестве объективной диагностики заболевания и прогнозирования тяжести течения патологии. В работе определяли концентрацию в плазме крови моноаминовых нейромедиаторов серотонина и дофамина, и нейротрофических факторов, участвующих в нейрогенезе (BDNF, CDNF и нейропептид Y) у пациентов с депрессией и здоровых добровольцев с одинаковыми социо-демографическими параметрами, используя методы иммуноферментного анализа и масс-спектрометрии. Все участники исследования были опрошены по шкале депрессии Гамильтона (HAMD), опроснику генерализованного тревожного расстройства (GAD-7) и опроснику центра эпидемиологических исследований (CES-D). Суммарный балл по трем исследованным шкалам у пациентов с депрессией существенно выше, чем в контрольной группе. Содержание серотонина, дофамина, BDNF, CDNF и нейропептида Y в плазме крови не отличалось в группах испытуемых и не было ассоциировано с баллами по шкалам. Обнаружены положительные корреляции содержания нейропептида Y и серотонина, BDNF и CDNF в плазме крови. Таким образом, данные маркеры хоть и связаны с патофизиологией депрессии, не коррелируют с тяжестью симптоматики и содержание их в плазме крови не отражает процессы, происходящие в мозге.

depressionHAMDCES-DGAD7BDNFCDNFneuropeptide YдепрессияHAMDCES-DGAD7BDNFCDNFнейропептид YRussian Science Foundation №20-14-00132Российский научный фонд №20-14-0013220-14-00132Hoifodt RS, Waterloo K, Wang CEA, et al. Cortisol levels and cognitive profile in major depression: A comparison of currently and previously depressed patients. Psychoneuroendocrinology. 2019;99:57–65. doi: 10.1016/j.psyneuen.2018.08.024Uddin M. Blood-based biomarkers in depression: emerging themes in clinical research. Mol Diagn Ther. 2014;18(5):469–482. doi: 10.1007/s40291-014-0108-1Belujon P, Grace AA. Dopamine System Dysregulation in Major Depressive Disorders. Int J Neuropsychopharmacol. 2017;20(12):1036–1046. doi: 10.1093/ijnp/pyx056Belujon P, Grace AA. Dopamine System Dysregulation in Major Depressive Disorders. Int J Neuropsychopharmacol. 2017;20(12):1036–1046. doi: 10.1093/ijnp/pyx056Pan JX, Xia JJ, Deng FL, et al. Diagnosis of major depressive disorder based on changes in multiple plasma neurotransmitters: a targeted metabolomics study. Transl Psychiatry. 2018;8(1):130. doi: 10.1038/s41398-018-0183-xKraus C, Castren E, Kasper S, Lanzenberger R. Serotonin and neuroplasticity — Links between molecular, functional and structural pathophysiology in depression. Neurosci Biobehav Rev. 2017;77:317–326. doi: 10.1016/j.neubiorev.2017.03.007Levy MJF, Boulle F, Steinbusch HW, et al. Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression. Psychopharmacology (Berl). 2018;235(8):2195–2220. doi: 10.1007/s00213-018-4950-4Liu W, Ge T, Leng Y, et al. The Role of Neural Plasticity in Depression: From Hippocampus to Prefrontal Cortex. Neural Plast. 2017;2017:6871089. doi: 10.1155/2017/6871089Yohn CN, Gergues MM, Samuels BA. The role of 5-HT receptors in depression. Mol Brain. 2017;10(1):28. doi: 10.1186/s13041-017-0306-ySchmidt HD, Duman RS. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behav Pharmacol. 2007;18(5–6):391–418. doi: 10.1097/FBP.0b013e3282ee2aa8Caviedes A, Lafourcade C, Soto C, Wyneken U. BDNF/NF-kappaB Signaling in the Neurobiology of Depression. Curr Pharm Des. 2017;23(21):3154–3163. doi: 10.2174/1381612823666170111141915Arosio B, Guerini FR, Voshaar RCO, Aprahamian I. Blood Brain-Derived Neurotrophic Factor (BDNF) and Major Depression: Do We Have a Translational Perspective? Front Behav Neurosci. 2021;15:626906. doi: 10.3389/fnbeh.2021.626906Klein AB, Williamson R, Santini MA, et al. Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int J Neuropsychopharmacol. 2011;14(3):347–353. doi: 10.1017/S1461145710000738Bocchio-Chiavetto L, Bagnardi V, Zanardini R, et al. Serum and plasma BDNF levels in major depression: a replication study and meta-analyses. World J Biol Psychiatry. 2010;11(6):763–773. doi: 10.3109/15622971003611319Brunoni AR, Lopes M, Fregni F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol. 2008;11(8):1169–1180. doi: 10.1017/S1461145708009309Karege F, Bondolfi G, Gervasoni N, et al. Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol Psychiatry. 2005;57(9):1068–1072. doi: 10.1016/j.biopsych.2005.01.008Schroter K, Brum M, Brunkhorst-Kanaan N, et al. Longitudinal multi-level biomarker analysis of BDNF in major depression and bipolar disorder. Eur Arch Psychiatry Clin Neurosci. 2020;270(2):169–181. doi: 10.1007/s00406-019-01007-yLindahl M, Saarma M, Lindholm P. Unconventional neurotrophic factors CDNF and MANF: Structure, physiological functions and therapeutic potential. Neurobiol Dis. 2017;97(Pt B):90–102. doi: 10.1016/j.nbd.2016.07.009Lin CQ, Chen LK. Cerebral dopamine neurotrophic factor promotes the proliferation and differentiation of neural stem cells in hypoxic environments. Neural Regen Res. 2020;15(11):2057–2062. doi: 10.4103/1673-5374.282262Galli E, Planken A, Kadastik-Eerme L, et al. Increased Serum Levels of Mesencephalic Astrocyte-Derived Neurotrophic Factor in Subjects With Parkinson’s Disease. Front Neurosci. 2019;13:929. doi: 10.3389/fnins.2019.00929Morales-Medina JC, Dumont Y, Quirion R. A possible role of neuropeptide Y in depression and stress. Brain Res. 2010;1314:194–205. doi: 10.1016/j.brainres.2009.09.077Geloso MC, Corvino V, Di Maria V, Marchese E, Michetti F. Cellular targets for neuropeptide Y-mediated control of adult neurogenesis. Front Cell Neurosci. 2015;9:85. doi: 10.3389/fncel.2015.00085Redrobe JP, Dumont Y, Fournier A, Baker GB, Quirion R. Role of serotonin (5-HT) in the antidepressant-like properties of neuropeptide Y (NPY) in the mouse forced swim test. Peptides. 2005;26(8):1394–1400. doi: 10.1016/j.peptides.2005.03.029Nahvi RJ, Sabban EL. Sex Differences in the Neuropeptide Y System and Implications for Stress Related Disorders. Biomolecules. 2020;10(9). doi: 10.3390/biom10091248Gotzsche CR, Woldbye DP. The role of NPY in learning and memory. Neuropeptides. 2016;55:79–89. doi: 10.1016/j.npep.2015.09.010Hou C, Jia F, Liu Y, Li L. CSF serotonin, 5-hydroxyindolacetic acid and neuropeptide Y levels in severe major depressive disorder. Brain Res. 2006;1095(1):154–158. doi: 10.1016/j.brainres.2006.04.026Irwin M, Brown M, Patterson T, et al. Neuropeptide Y and natural killer cell activity: findings in depression and Alzheimer caregiver stress. FASEB J. 1991;5(15):3100–3107. doi: 10.1096/fasebj.5.15.1743441Czermak C, Hauger R, Drevets WC, et al. Plasma NPY concentrations during tryptophan and sham depletion in medication-free patients with remitted depression. J Affect Disord. 2008;110(3):277–281. doi: 10.1016/j.jad.2008.01.014Tural U, Iosifescu DV. Neuropeptide Y in PTSD, MDD, and chronic stress: A systematic review and meta-analysis. J Neurosci Res. 2020;98(5):950–963. doi: 10.1002/jnr.24589Ozsoy S, Olguner Eker O, Abdulrezzak U. The Effects of Antidepressants on Neuropeptide Y in Patients with Depression and Anxiety. Pharmacopsychiatry. 2016;49(1):26–31. doi: 10.1055/s-0035-1565241Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62. doi: 10.1136/jnnp.23.1.56Radloff LS. The CES-D scale: A self-report depression scale for research in the general population. Applied psychological measurement. 1977;1(3):385–401.Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092–1097. doi: 10.1001/archinte.166.10.1092Cowen PJ, Browning M. What has serotonin to do with depression? World Psychiatry. 2015;14(2):158–160. doi: 10.1002/wps.20229Holck A, Wolkowitz OM, Mellon SH, Reus VI, Nelson JC, Westrin Å, Lindqvist D. Plasma serotonin levels are associated with antidepressant response to SSRIs. J Affect Disord. 2019 May 1;250:65–70. doi: 10.1016/j.jad.2019.02.063. Epub 2019 Feb 26. PMID: 30831543; PMCID: PMC6699768.Mosolov SN. Diagnosis and Treatment of Depression in Patients with Schizophrenia. Consortium Psychiatricum. 2020;1(2):29–42. doi: 10.17650/2712-7672-2020-1-2-29-42Takada A, Shimizu F, Takao T. [Tryptophan Metabolites in Plasma of Patients with Depression]. Brain Nerve. 2018 Sep;70(9):1025–1031. Japanese. doi: 10.11477/mf.1416201123. PMID: 30177580.Blardi P, de Lalla A, Auteri A, et al. Plasma catecholamine levels after fluoxetine treatment in depressive patients. Neuropsychobiology. 2005;51(2):72–76. doi: 10.1159/000084163Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry. 1997;54(7):597–606. doi: 10.1001/archpsyc.1997.01830190015002Hashimoto H, Onishi H, Koide S, Kai T, Yamagami S. Plasma neuropeptide Y in patients with major depressive disorder. Neurosci Lett. 1996;216(1):57–60. doi: 10.1016/0304-3940(96)13008-1Dryden S, Frankish HM, Wang Q, Pickavance L, Williams G. The serotonergic agent fluoxetine reduces neuropeptide Y levels and neuropeptide Y secretion in the hypothalamus of lean and obese rats. Neuroscience. 1996;72(2):557–566. doi: 10.1016/0306-4522(95)00566-8Mori RC, Telles MM, Guimaraes RB, et al. Feeding induced by increasing doses of neuropeptide Y: dual effect on hypothalamic serotonin release in normal rats. Nutr Neurosci. 2004;7(4):235–239. doi: 10.1080/1028415040001279